Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years and older. Various causes, including genetic susceptibility, environmental risk factors, and exposures have been suggested in the literature. All of these cause repetitive micro-injury to the lung tissue and vasculature, which triggers a cascade of inflammatory response and fibrosis. 


Idiopathic Pulmonary Fibrosis symptoms are similar to other lung diseases, like asthma and chronic obstructive lung disease (COPD); this results in misdiagnosis of initial presentation.


Idiopathic Pulmonary Fibrosis Epidemiological Segmentation 

The Epidemiological Segmentation of Idiopathic Pulmonary Fibrosis in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent cases of Idiopathic Pulmonary Fibrosis
  • Gender-specific cases of Idiopathic Pulmonary Fibrosis
  • Age-specific cases of Idiopathic Pulmonary Fibrosis
  • Severity-specific cases of Idiopathic Pulmonary Fibrosis


Idiopathic Pulmonary Fibrosis Epidemiology 

  • The total prevalent population of IPF in the 7MM is expected to rise to 284,823 by 2030.
  • IPF affects approximately 132,000 people in the US with about 50,000 new diagnoses every year.


Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis Market Size in the 7MM in 2017 was 1,510 Million.


Idiopathic Pulmonary Fibrosis Market Drivers

  • The grant of special regulatory designations
  • Several therapies in the pipeline from various companies
  • An increase in the prevalence of fibrotic diseases

 

Idiopathic Pulmonary Fibrosis Market Barriers

  • The prognosis of patients with IPF remains poor
  • lack of accurate diagnostic procedures and specific validating biomarkers
  • IPF is associated with high mortality rates


Idiopathic Pulmonary Fibrosis Emerging Drugs

The emerging drugs of the Idiopathic Pulmonary Fibrosis market are 

  • TipelukastPamrevlumab
  • KD025
  • PRM 151
  • GLPG1690

And many others. 


Idiopathic Pulmonary Fibrosis Key Players

The key players in the Idiopathic Pulmonary Fibrosis market are

  • MediciNova
  • FibroGen
  • Kadmon Corporation, LLCs
  • Promedior, Inc.
  • Galapagos NV

And many others.